Answers are grounded in this paper and cite their sources.
BACKGROUND: Weight loss is a common complication during radiotherapy for head and neck cancer and may adversely affect treatment tolerance and outcomes. We evaluated whether megestrol acetate (MA) prevents treatment-related weight loss. METHODS: In this multicenter, open-label randomized controlled trial, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma undergoing radiotherapy were assigned to MA plus standard care or standard care alone. Standard care consisted of nutritional counseling, symptom management, and feeding-tube placement when clinically indicated. The primary endpoint was change in body weight from baseline to 6 weeks post-radiotherapy. RESULTS: At 6 weeks post-radiotherapy, the MA group showed a mean weight gain of 2.07 kg, whereas the control group lost 1.74 kg (p < 0.01). Weight gain was primarily due to increased fat mass, with no significant difference in muscle mass. Quality of life was similar between groups. CONCLUSION: MA improved weight preservation during radiotherapy and may serve as an adjunct to supportive care in head and neck cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: TCTR20240330005.
No takes yet. Share an insight, caveat, or question.
Muangwong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: